Here, we have shown that in severe models of renal disease, pharmaco-genetic inhibition of DDR1 expression by antisense administration can arrest the progression of nephropathy, providing thus for the first time a proof of concept of a treatment based on DDR1 blockade. Here, DDR1 is linked to kidney disorder.